Worldleish

An International Congress on Leishmania & Leishmaniasis

Why ?  Cutaneous, mucocutaneous and visceral leishmaniases are serious diseases, which are vector-borne and wide-spread in more than 90 countries, putting 350 million population at risk. WHO estimates an annual incidence of 2 million and a total of 12 million current cases. The causative agents are various species of trypanosomatid protozoa in the genus of Leishmania, which are excellent models for aspects of laboratory studied in cell/molecular biology, biochemistry, immunology of host-parasite interactions.

Who ? Anyone interested in Leishmania and leishmaniasis is welcome to participate, including individuals of private and public academic institutions, charitable organizations, advocacy groups, government officials/ representatives, for-profit private sectors and their friends/affiliates.

 When/where ? Every four years preferably in a country endemic to leishmaniasis.

What ? Bring laboratory researchers and field workers from all disciplinary areas together for sharing new discoveries and exchange of new ideas. Provide opportunities of international collaboration, industrial participation, charitable donation and training of the next generation.

WL topics include, but are not limited to the following subjects:

  • Molecular/cell biology       
  • Virulence factors       
  • Host-parasite cellular and molecular interactions in vitro
  • Genetics/genomics/taxonomy       
  • Drug development: Conventional and alternative       
  • Alternative therapies: topical thermotherapy, etc.       
  • Drug resistance/mechanisms       
  • Diagnostic methodology in practice and under development       
  • Clinical and experimental immunopathology/pathogenic mechanisms       
  • Clinical and experimental therapy       
  • Clinical and experimental immunology       
  • Clinical and experimental vaccination       
  • Clinical presentation       
  • Epidemiology: Incidence and risk factors      
  • Ecology: Urbanization & sylvatic cycle       
  • Asymptomatic infection       
  • Leishmania-HIV co-infection       
  • Vector biology and molecular biology       
  • Reservoir       
  • Canine leishmaniasis       
  • Animal model/genetic susceptibility       
  • Operational health       
  • Control programs       
  • National and international funding organizations